Clinical Trial Update: TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating TACE combined with Tilelizumab and Sorafenib for BCLC Stage C hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sorafenib (Sorafenib)
• TACE (transarterial chemoembolization) (transarterial chemoembolization)
• Tilelizumab (investigational) (Tilelizumab)

Snippet

Sponsor: First Affiliated Hospital of Zhejiang University | Conditions: BCLC Stage C Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN